GSK-Pfizer deal illustrates risks and rewards of moving up the biopharma value chain
The potential rewards for drugmakers' investments in pharmaceuticals and vaccines are enormous, but so are the risks, an industry consultant said.
The potential rewards for drugmakers' investments in pharmaceuticals and vaccines are enormous, but so are the risks, an industry consultant said.
The British drugmaker plans to separate the consumer health joint venture with Pfizer announced Wednesday three years after the transaction closes.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.